Cargando…
Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good ch...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666198/ https://www.ncbi.nlm.nih.gov/pubmed/36397446 http://dx.doi.org/10.1097/MD.0000000000031784 |
_version_ | 1784831450450755584 |
---|---|
author | Qiu, Yue Zhang, Weishu Li, Guanru Guo, Xinwei Qu, Jianhua Lan, Haibing Zhang, Cang Xu, Jingna Sun, Liyun |
author_facet | Qiu, Yue Zhang, Weishu Li, Guanru Guo, Xinwei Qu, Jianhua Lan, Haibing Zhang, Cang Xu, Jingna Sun, Liyun |
author_sort | Qiu, Yue |
collection | PubMed |
description | Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good choice for the treatment of psoriasis, which has been proved to be safe and effective, and may reduce the recurrence rate. In clinical practice, Liangxue Jiedu Runzhi (LJR) ointment can effectively treat mild and moderate psoriasis with blood-heat syndrome, but there is a lack of evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of LJR ointment for the treatment of mild and moderate psoriasis with blood-heat syndrome. METHODS: A multicenter, randomized, double-blind, placebo-controlled, and self-controlled clinical trial was carried out according to this paper. The symmetrical rashes of each subject were regarded as the target lesions and were randomly divided into a treatment group (LJR ointment group) and a control group (placebo group). The LJR ointment or placebo ointment were externally administered on bilateral symmetric rashes, twice a day for eight weeks. The follow-up examination was made for subjects every two weeks. The primary research finding was conveyed by Psoriasis Area and Severity Index (PASI) in 8 weeks. The secondary research finding includes adverse events. RESULTS: 46 subjects undergo this research project. The difference between PASI scores of the target lesions in the treatment group and control group is statistically significant were in 8 weeks (P < .001). The percentage of PASI 75 in treatment group and control group were 48% and 15% in week 8, respectively (x(2) = 11.33, P < .05). No severe adverse events were reported. CONCLUSIONS: LJR ointment was proved to have efficacy in the treatment of mild and moderate psoriasis with the blood-heat syndrome. |
format | Online Article Text |
id | pubmed-9666198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-96661982022-11-16 Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial Qiu, Yue Zhang, Weishu Li, Guanru Guo, Xinwei Qu, Jianhua Lan, Haibing Zhang, Cang Xu, Jingna Sun, Liyun Medicine (Baltimore) 4000 Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good choice for the treatment of psoriasis, which has been proved to be safe and effective, and may reduce the recurrence rate. In clinical practice, Liangxue Jiedu Runzhi (LJR) ointment can effectively treat mild and moderate psoriasis with blood-heat syndrome, but there is a lack of evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of LJR ointment for the treatment of mild and moderate psoriasis with blood-heat syndrome. METHODS: A multicenter, randomized, double-blind, placebo-controlled, and self-controlled clinical trial was carried out according to this paper. The symmetrical rashes of each subject were regarded as the target lesions and were randomly divided into a treatment group (LJR ointment group) and a control group (placebo group). The LJR ointment or placebo ointment were externally administered on bilateral symmetric rashes, twice a day for eight weeks. The follow-up examination was made for subjects every two weeks. The primary research finding was conveyed by Psoriasis Area and Severity Index (PASI) in 8 weeks. The secondary research finding includes adverse events. RESULTS: 46 subjects undergo this research project. The difference between PASI scores of the target lesions in the treatment group and control group is statistically significant were in 8 weeks (P < .001). The percentage of PASI 75 in treatment group and control group were 48% and 15% in week 8, respectively (x(2) = 11.33, P < .05). No severe adverse events were reported. CONCLUSIONS: LJR ointment was proved to have efficacy in the treatment of mild and moderate psoriasis with the blood-heat syndrome. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666198/ /pubmed/36397446 http://dx.doi.org/10.1097/MD.0000000000031784 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4000 Qiu, Yue Zhang, Weishu Li, Guanru Guo, Xinwei Qu, Jianhua Lan, Haibing Zhang, Cang Xu, Jingna Sun, Liyun Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title | Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title_full | Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title_fullStr | Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title_full_unstemmed | Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title_short | Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial |
title_sort | liangxue jiedu runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: a double-blind randomized controlled trial |
topic | 4000 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666198/ https://www.ncbi.nlm.nih.gov/pubmed/36397446 http://dx.doi.org/10.1097/MD.0000000000031784 |
work_keys_str_mv | AT qiuyue liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT zhangweishu liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT liguanru liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT guoxinwei liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT qujianhua liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT lanhaibing liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT zhangcang liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT xujingna liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial AT sunliyun liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial |